Neuromodulation has emerged as a leading main stream treatment approach for a broad range of conditions from pain management to complex brain conditions, such as Alzheimer’s and Parkinson’s disease.
Medergie has embarked on the development of a universal neuromodulation platform that will serve as a building block to be used in various therapies and modalities.
Medergie has negotiated a licensing agreement with EMED Technologies Corporation in the USA, to collaborate on the world-wide clinical deployment of the Detrusan Neuromodulation System.
The Detrusan Neuromodulation System is a revolutionary treatment for female urge and stress urinary incontinence. The treatment utilizes groundbreaking neuromodulation technology that retrains the bladder system and restores normal function. The technology has been used to successfully treat over 100 difficult cases of female urinary incontinence in hospitals in the USA.
Detrusan treatments involve 30-min stimulation procedures that are delivered in a professional clinical environment. Patients have reported complete relief from symptoms after as little as three treatment sessions.
“I have now treated over 500 patients with this modality. At first, I was somewhat skeptical about its value, but after first hand witnessing the marked improvement in the majority of these patients’ bladder control symptoms, I am now firmly convinced of its utility."
--Dr. J. S. Hardesty M.D., Prof. Gynecology and Obstetrics, Loma Linda University School of Medicine, California.
Read more at: www.detrusan.com
